Hemostemix Inc. (HEM.V)
Hemostemix Inc.
707-7th Avenue SW
Suite 1150
Calgary, AB T2P 3H6
Canada
905-580-4170
https://hemostemix.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees:
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Thomas A. Smeenk B.A., BA Hons | Co-Founder, President, CEO & Director | 308k | N/A | 1962 |
| Ms. Christina Wu CPA | Interim Chief Financial Officer | 65.38k | N/A | N/A |
| Peter Pavlin | Vice President of Operations | N/A | N/A | N/A |
| Dr. Fraser C. Henderson Sr., M.D. | Chief Medical Officer | N/A | N/A | N/A |
Description
Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions. The company develops cell therapy products from the patient's own blood, which is a non-invasive source of therapeutic cells. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia in Canada and the United States. The company is also developing various types of cell products, such as synergetic cell populations, neural cell precursors, and cardiomyocyte cell precursors. Hemostemix Inc. is headquartered in Calgary, Canada.
Corporate Governance
Hemostemix Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
